• Explore /
  • Poster
  • / Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial.

Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial.

Abstract Poster

Authors

null

Sina Buchholz

Ulm University Hospital, Department of Internal Medicine I, Ulm, Germany;

Sina Buchholz , Thomas Jens Ettrich , Waldemar Uhl , Marko Kornmann , Hana Algül , Helmut Friess , Alexander Koenig , Eike Gallmeier , Manfred P. Lutz , Kai Wille , Carl Christoph Schimanski , Volker Kunzmann , Michael Geissler , Dirk Waldschmidt , Severin Daum , Lukas Perkhofer , Anke C. Reinacher-Schick , Thomas Seufferlein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Quality of Care/Quality Improvement

Clinical Trial Registration Number

NCT02047513

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 694)

DOI

10.1200/JCO.2023.41.4_suppl.694

Abstract #

694

Poster Bd #

K1

Abstract Disclosures

Similar Posters

First Author: Thomas Jens Ettrich

First Author: Waldemar Uhl

First Author: Derek B. Grose

First Author: Efrat Dotan